Jubilant & Gilead signed licensing deal for Remdesivir

US-based Gilead Sciences and India’s Jubilant Life Sciences signed a licensing agreement for production of remdesivir drug which has been identified as a potential therapy for novel coronavirus. The licensing agreement is for India and 127 other low, middle income and upper middle income countries and the Noida-based company will market the drug.

Jubilant Life Sciences chairman Shyam Bhartia and managing director Hari S Bhartia said that, “We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug’s active pharmaceutical ingredient (API) in-house helping its cost effectiveness and consistent availability.”

Remdesivir is the most watched drugs against the treatment of Covid-19. It received an emergency approval in April from the US Food and Drug Administration (USFDA), making it the first authorised therapy for the virus. The USFDA’s approval was according to the trial results which showed that the drug reduced the recovery time to five days from 10 days for moderate patients.

  • Related Posts

    • Pharma
    • July 22, 2025
    • 149 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    • Pharma
    • July 16, 2025
    • 577 views
    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug